Robin L. Jones, MBBS, MRCP, MD, Institute of Cancer Research in London, highlights key sessions in sarcoma at the ESMO 2023 Congress. He particularly commends the retroperitoneal sarcoma session for its comprehensive multidisciplinary discussion on treatment approaches. Notably, the oral abstract session featured a presentation by the French Sarcoma Group on a Phase III randomized trial (NCT02997358) exploring doxorubicin plus trabectedin versus doxorubicin alone in patients with metastatic or unresectable leiomyosarcoma, revealing significant benefits in progression-free survival (PFS) and overall survival (OS) with the combination. Prof. Jones underscores the importance of such findings in advancing sarcoma treatment strategies. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
